Diagnostic Performance of<sup>124</sup>I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
Manuel Weber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Wolfgang P. Fendler(Essen University Hospital), Nicole Unger(Essen University Hospital), Martin K. Walz(Kliniken Essen-Mitte), Frank Weber(Ludwig-Maximilians-Universität München), Christoph Rischpler(Essen University Hospital), Ines Maríc(Essen University Hospital), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Jochen Schmitz(Essen University Hospital), Thorsten D. Poeppel(Klinik und Poliklinik für Nuklearmedizin), Ken Herrmann(Essen University Hospital), Sarah Theurer(Essen University Hospital), Walter Jentzen(Essen University Hospital)
Cited by 21
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306
Comprehensive Re-Sequencing of Adrenal Aldosterone Producing Lesions Reveal Three Somatic Mutations near the KCNJ5 Potassium Channel Selectivity Filter
|PLoS ONE|2012|184
Activating mutations in CTNNB1 in aldosterone producing adenomas
|Scientific Reports|2016|172